InVivoMAb Human AS Fc Block™ (Iv0017)

Catalog No.

VHK25301

Species reactivity

Human

Host species

Human

Isotype

IgG1, kappa

Clonality

Monoclonal

Target

CD16, CD32, Low affinity immunoglobulin gamma Fc region receptor III, IgG Fc receptor III, Fc-gamma RIII, FcRIII, CD16, Fcgr3, Low affinity immunoglobulin gamma Fc region receptor II, Fc gamma receptor IIB, Fc-gamma RII, Fc-gamma-RIIB, FcRII, IgG Fc receptor II beta, Lymphocyte antigen 17, Ly-17, CD32, Fcgr2, Fcgr2b, Ly-17

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Applications

Neutralization

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Clone ID

Iv0017

In vivo screen of Plasmodium targets for mosquito-based malaria control., PMID:40399670

Potential of recombinant CAV1-Fc in the treatment of ApxI toxin-induced damage by Actinobacillus pleuropneumoniae., PMID:40215801

Attenuation of cardiac ischemia/reperfusion injury via the decoy receptor DcR2 by targeting the PLAD domain of the death receptor DR5., PMID:40154678

New soluble CSF-1R-dimeric mutein with enhanced trapping of both CSF-1 and IL-34 reduces suppressive tumor-associated macrophages in pleural mesothelioma., PMID:40101804

FcγRIIB (CD32B) antibodies enhance immune responses through activating FcγRs., PMID:40089806

Maplirpacept: a CD47 decoy receptor with minimal red blood cell binding and robust anti-tumor efficacy., PMID:40078999

Suppression of NF-κB and downstream XBP1 by DcR3 contributes to a decrease in antibody secretion., PMID:40073262

Blockade of αvβ6 and αvβ8 integrins with a chromogranin A-derived peptide inhibits TGFβ activation in tumors and suppresses tumor growth., PMID:40055773

Fc-competent TIGITx4-1BB bispecific antibody exerts potent long-lasting antitumor activity by potentiating CD8+ T cell activity and Fcγ receptor-mediated modulation of the tumor microenvironment., PMID:40010766

The Dose-Dependent Effects of Fluorocitrate on the Metabolism and Activity of Astrocytes and Neurons., PMID:40002432

Silibinin, a PLC-β3 inhibitor, inhibits mast cell activation and alleviates OVA-induced asthma., PMID:39870013

Tensile force promotes osteogenic differentiation via ephrinB2-EphB4 signaling pathway in orthodontic tooth movement., PMID:39844202

A humanized anti-MSLN×4-1BB bispecific antibody exhibits potent antitumour activity through 4-1BB signaling activation and fc function without systemic toxicity., PMID:39806351

Fc Effector Function of Immune Checkpoint Blocking Antibodies in Oncology., PMID:39663733

Dual blockade of IL-17A and IL-36 pathways via a bispecific antibody exhibits enhanced anti-inflammatory potency., PMID:39600699

GALNT6, transcriptionally inhibited by KLF9, promotes osteosarcoma progression by increasing EFEMP1 expression via O-glycosylation modification., PMID:39581475

Cost-Effective DNA Storage System with DNA Movable Type., PMID:39555674

Targeted hematopoietic stem cell depletion through SCF-blockade., PMID:39473008

The active ingredient of Evodia rutaecarpa reduces inflammation in knee osteoarthritis rats through blocking calcium influx and NF-κB pathway., PMID:39434543

The relevance of tumor target expression levels on IgA-mediated cytotoxicity in cancer immunotherapy., PMID:39358557

Cell-cell contact-dependent secretion of large-extracellular vesicles from EFNBhigh cancer cells accelerates peritoneal dissemination., PMID:39003372

Combining CD38 antibody with CD47 blockade is a promising strategy for treating hematologic malignancies expressing CD38., PMID:38983860

Enhancing Neutrophil Cytotoxicity of a Panel of Clinical EGFR Antibodies by Fc Engineering to IgA3.0., PMID:38958494

[A recombinant adeno-associated virus expressing secretory TGF-β type Ⅱ receptor inhibits triple-negative murine breast cancer 4T1 cell proliferation and lung metastasis in mice]., PMID:38862439

Enhanced IL-15-mediated NK cell activation and proliferation by an ADAM17 function-blocking antibody involves CD16A, CD137, and accessory cells., PMID:38798522

Promising Effects of Casearins in Tumor-Bearing Mice and Antinociceptive Action against Oncologic Pain: Molecular Docking and In Vivo Findings., PMID:38794204

Targeting CEACAM5-positive solid tumors using NILK-2401, a novel CEACAM5xCD47 κλ bispecific antibody., PMID:38720892

Human coronavirus OC43 nanobody neutralizes virus and protects mice from infection., PMID:38709106

Aspecific binding of anti-NK1.1 antibodies on myeloid cells in an experimental model for malaria-associated acute respiratory distress syndrome., PMID:38637828

Characterization of a novel anti-PVRIG antibody with Fc-competent function that exerts strong antitumor effects via NK activation in preclinical models., PMID:38554184

IgG hexamers initiate complement-dependent acute lung injury., PMID:38530369

C1q enables influenza hemagglutinin stem binding antibodies to block viral attachment and broadens the antibody escape repertoire., PMID:38517951

Rapid unleashing of macrophage efferocytic capacity via transcriptional pause release., PMID:38480883

Development of a Bispecific IgG1 Antibody Targeting BCMA and PDL1., PMID:38390876

Human Fc gamma receptor IIIA blockade inhibits platelet destruction in a humanized murine model of ITP., PMID:38330193

IgG hexamers initiate acute lung injury., PMID:38328049

mIgM-mediated splenic marginal zone B cells targeting of folic acid for immunological evasion., PMID:38322341

JAGGER localization and function are dependent on GPI anchor addition., PMID:38294499

Leukocyte-associated immunoglobulin-like receptor-1 blockade in combination with programmed death-ligand 1 targeting therapy mediates increased tumour control in mice., PMID:38236251

Dual-modality probe nanodrug delivery systems with ROS-sensitivity for atherosclerosis diagnosis and therapy., PMID:38230621

Administration of an AAV vector coding for a P2X7-blocking nanobody-based biologic ameliorates colitis in mice., PMID:38212782

A highly potent anti-VISTA antibody KVA12123 - a new immune checkpoint inhibitor and a promising therapy against poorly immunogenic tumors., PMID:38152397

A nanobody inhibiting porcine reproductive and respiratory syndrome virus replication via blocking self-interaction of viral nucleocapsid protein., PMID:38084961

Fcγ receptors and immunomodulatory antibodies in cancer., PMID:38062252

The anticancer application of half-sandwich iridium(III) ferrocene-thiosemicarbazide Schiff base complexes., PMID:38054240

Targeting transforming growth factor beta signaling in metastatic osteosarcoma., PMID:38021074

The anti-B7-H3 blocking antibody MJ18 does not recognize B7-H3 in murine tumor models., PMID:38014341

A novel single domain bispecific antibody targeting VEGF and TNF-α ameliorates rheumatoid arthritis., PMID:37992444

Targeting the aryl hydrocarbon receptor (AhR) with BAY 2416964: a selective small molecule inhibitor for cancer immunotherapy., PMID:37963637

The novel high-affinity humanized antibody IMM40H targets CD70, eliminates tumors via Fc-mediated effector functions, and interrupts CD70/CD27 signaling., PMID:37849799

Document Download

InVivoMAb Human AS Fc Block™ (Iv0017).pdf